None of the 29 investors followed here reported a position in ZLAB in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ZLAB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Chen YajingChief Financial Officer | — | 920 | — |
| Aug 18, 2026 | Chen YajingChief Financial Officer | Sale at price 27.00 per share. | 260 | $7.02K |
| Aug 13, 2026 | Chen YajingChief Financial Officer | — | 1.3K | — |
| Aug 11, 2026 | Lis William DavidDirector | Sale at price 25.00 per share. | 8.5K | $212.65K |
| Aug 10, 2026 | Chen YajingChief Financial Officer | Sale at price 25.00 per share. | 619 | $15.47K |
| Jul 1, 2026 | Du Ying SamanthaChief Executive Officer | — | 29K | — |
| Jun 30, 2026 | Gaynor Richard Brian M.D.Director | Purchase at price 19.05 per share. | 1.7K | $33.07K |
| Jun 29, 2026 | Du Ying SamanthaChief Executive Officer | Sale at price 18.53 per share. | 7K | $130.22K |
| Jun 28, 2026 | Du Ying SamanthaChief Executive Officer | — | 18K | — |
| Jun 25, 2026 | Edmondson Frazor Titus IiiOfficer | Sale at price 17.46 per share. | 4.1K | $71.64K |
| Jun 25, 2026 | Chen YajingChief Financial Officer | Sale at price 17.46 per share. | 2.3K | $39.53K |
| Jun 25, 2026 | Du Ying SamanthaChief Executive Officer | Sale at price 17.46 per share. | 24.5K | $428.55K |
| Jun 24, 2026 | Edmondson Frazor Titus IiiOfficer | — | 14.6K | — |
| Jun 24, 2026 | Chen YajingChief Financial Officer | — | 6.3K | — |
| Jun 24, 2026 | Du Ying SamanthaChief Executive Officer | — | 58.8K | — |
| Jun 21, 2026 | Lis William DavidDirector | Sale at price 18.09 per share. | 7K | $127.35K |
| Jun 16, 2026 | Diekman John DavidDirector | Stock Award(Grant) at price 0.00 per share. | 22.4K | — |
| Jun 16, 2026 | Wirth Peter Karl J.D.Director | Stock Award(Grant) at price 0.00 per share. | 22.4K | — |
| Jun 16, 2026 | Moulder Leon Oliver Jr.Director | Stock Award(Grant) at price 0.00 per share. | 22.4K | — |
| Jun 16, 2026 | Lis William DavidDirector | Stock Award(Grant) at price 0.00 per share. | 22.4K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.9 | 15.8 | -2.1 | 15.0 | -18.3 | 7.4 | -3.8 | 39.4 | 3.5 | -6.6 | +39.4% | ||
| 2025 | 3.8 | 27.4 | 4.3 | -12.3 | -4.9 | 16.0 | 8.1 | -12.4 | 2.4 | -22.9 | -21.9 | -13.6 | −32.6% |
| 2024 | -21.1 | -2.7 | -23.6 | -1.4 | 12.5 | -2.5 | 9.8 | 4.8 | 21.1 | 25.2 | -4.5 | -9.2 | −4.2% |
| 2023 | 37.3 | -11.8 | -10.5 | 5.2 | -7.1 | -14.7 | 8.4 | -15.3 | -4.6 | 3.7 | 8.3 | 0.1 | −11.0% |
| 2022 | -21.0 | 10.1 | -19.6 | -9.1 | -27.2 | 19.2 | 16.9 | 14.0 | -26.0 | -34.9 | 73.1 | -20.4 | −51.2% |
| 2021 | 18.3 | -7.8 | -9.6 | 24.6 | 6.9 | -0.4 | -18.3 | -0.1 | -27.1 | -0.9 | -33.7 | -9.2 | −53.6% |
| 2020 | 22.6 | 7.8 | -6.3 | 21.8 | 18.6 | 10.4 | -7.3 | 4.3 | 4.8 | -1.3 | 35.0 | 22.2 | +225.4% |
| 2019 | 16.2 | 6.8 | 2.4 | -9.7 | -1.7 | 33.0 | -7.9 | 1.5 | -0.8 | 4.5 | 17.8 | 4.5 | +79.1% |
| 2018 | 27.0 | -17.8 | -3.6 | -12.6 | 25.4 | -0.7 | -5.7 | 3.7 | -14.3 | -16.0 | 20.5 | 17.7 | +9.4% |
| 2017 | 0.0 | -3.3 | -18.7 | −21.4% |
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Buy / hold / sell counts